Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CGON

Cg Oncology Inc

Feb 06 • 04:00PM ET

50.36

+1.16 2.36 %

Healthcare • Biotechnology • USA • NASD

Peers: ONC BPMC EXEL PTCT PBYI FATE KURA MGNX GERN IMMP

| Held by: VTI XBI IWM VB VBR VXF IWO IBB SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.98	Insider Own	37.18%	Shs Outstand	78.28M	Perf Week	-3.25%
Market Cap	4.06B	Forward P/E	-	EPS next Y	-2.61	Insider Trans	4.63%	Shs Float	50.68M	Perf Month	18.63%
Enterprise Value	3.39B	PEG	-	EPS next Q	-0.60	Inst Own	77.54%	Short Float	18.52%	Perf Quarter	32.67%
Income	-151.48M	P/S	1872.05	EPS this Y	-54.31%	Inst Trans	2.03%	Short Ratio	8.72	Perf Half Y	106.82%
Sales	2.17M	P/B	5.73	EPS next Y	-20.04%	ROA	-23.63%	Short Interest	9.39M	Perf YTD	21.29%
Book/sh	8.78	P/C	5.97	EPS next 5Y	-17.47%	ROE	-24.74%	52W High	57.88 -12.99%	Perf Year	66.09%
Cash/sh	8.43	P/FCF	-	EPS past 3/5Y	-61.21% -	ROIC	-21.83%	52W Low	14.80 240.27%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-52.09% -	Gross Margin	-	Volatility	5.85% 6.94%	Perf 5Y	-
Dividend TTM	-	EV/Sales	1561.90	EPS Y/Y TTM	-85.53%	Oper. Margin	-8285.33%	ATR (14)	2.88	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	22.74	Sales Y/Y TTM	217.84%	Profit Margin	-6967.99%	RSI (14)	50.15	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	22.79	EPS Q/Q	-113.10%	SMA20	-6.00%	Beta	1.38	Target Price	79.21
Payout	-	Debt/Eq	0.01	Sales Q/Q	3774.42%	SMA50	8.96%	Rel Volume	0.78	Prev Close	49.20
Employees	113	LT Debt/Eq	0.01	Earnings	Nov 14 BMO	SMA200	44.06%	Avg Volume	1.08M	Price	50.36
IPO	Jan 25, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1.97% 2704.71%	Trades		Volume	841,672	Change	2.36%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-25	Initiated	Wedbush	Outperform	$70
Nov-24-25	Initiated	Truist	Buy
Oct-08-25	Initiated	Guggenheim	Buy	$90
Aug-19-25	Initiated	Piper Sandler	Overweight	$55
Jul-10-25	Resumed	Goldman	Buy	$40
May-02-25	Initiated	JP Morgan	Overweight	$41
Apr-16-25	Initiated	Scotiabank	Sector Perform	$23
Jan-07-25	Initiated	TD Cowen	Buy
Oct-24-24	Initiated	UBS	Buy	$60
Sep-23-24	Initiated	RBC Capital Mkts	Outperform	$66
Aug-28-24	Initiated	ROTH MKM	Buy	$65
Jun-28-24	Initiated	BofA Securities	Buy	$65
Feb-20-24	Initiated	Morgan Stanley	Overweight	$55
Feb-20-24	Initiated	Goldman	Neutral	$42
Feb-20-24	Initiated	Cantor Fitzgerald	Overweight	$75
Feb-14-24	Initiated	H.C. Wainwright	Buy	$75

Show Previous Ratings

Jan-15-26 10:26AM	CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why (Zacks)
Jan-12-26 10:35AM	Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 (PR Newswire)
Jan-09-26 08:30AM	CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC (GlobeNewswire) +29.26%
Jan-06-26 08:00AM	CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-25 08:00AM	SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award (GlobeNewswire)
12:20AM	Loading…
Dec-09-25 12:20AM	CG Oncology, Inc. (CGON) is a Buy on Cancer Treatment Development: Truist Securities (Insider Monkey)
Dec-05-25 08:30AM	New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Nov-26-25 07:00AM	CG Oncology Announces New Board Member and Board Transition (GlobeNewswire)
Nov-25-25 04:05PM	CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting (GlobeNewswire)
Nov-17-25 09:26AM	Company News for Nov 17, 2025 (Zacks)
Nov-14-25 09:10AM	CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +8.61%
08:00AM	CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-06-25 08:10AM	ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Oct-17-25 09:55PM	CG Oncology (CGON) Gets Initiated With a Buy at Guggenheim (Insider Monkey) +5.14%
Oct-16-25 04:33PM	Guggenheim Initiates CG Oncology (CGON) Coverage with $90 PT, Highlights Bladder Cancer Therapeutic Cretostimogene (Insider Monkey)
06:14PM	Loading…
Oct-08-25 06:14PM	Why Cg Oncology Stock Rocketed 7% Higher Today (Motley Fool) +7.13% +9.21%
Sep-22-25 03:19AM	CG Oncology (CGON) PT Raised to $79 by Morgan Stanley on Strong Clinical Pipeline for Bladder Cancer Treatment (Insider Monkey)
Sep-19-25 09:20AM	Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength? (Zacks)
Sep-18-25 10:03AM	CG Oncology, Inc. (CGON) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Sep-08-25 09:30AM	Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market (PR Newswire)
Sep-05-25 07:00AM	CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months (GlobeNewswire) +6.88%
Sep-03-25 08:00AM	CG Oncology Completes Enrollment in PIVOT-006 (GlobeNewswire)
Aug-29-25 08:00AM	CG Oncology's Executive Leadership to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 12:14AM	CG Oncology's Bladder Cancer Drug Shows Strong Clinical Data, Drives Optimism Despite Price Target Cut (Insider Monkey)
12:13AM	H.C. Wainwright Reiterates a Buy on CG Oncology (CGON), Keeps the PT (Insider Monkey)
Aug-08-25 08:00AM	CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-06-25 08:40AM	Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates (Zacks) -6.12%
Jul-31-25 11:58AM	CG Oncology, Inc. (CGON) Reports 75.5% Complete Response in Bladder Cancer Trial (Insider Monkey)
Jul-29-25 04:05PM	Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals (GlobeNewswire)
Jul-07-25 08:30AM	Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs (PR Newswire)
04:15AM	Loading…
Jul-06-25 04:15AM	Morgan Stanley Lifts PT on CG Oncology (CGON) to $56, Keeps an Overweight Rating (Insider Monkey)
Jul-01-25 02:30PM	Lustgarten Foundation Appoints Arthur Kuan, MS, to Board of Directors (PR Newswire)
Jun-18-25 11:19AM	Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going (PR Newswire)
Jun-05-25 08:00AM	CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-22-25 08:46AM	CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success (Zacks)
May-15-25 08:00AM	CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-14-25 09:38AM	Company News for May 14, 2025 (Zacks)
May-13-25 09:10AM	CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
07:45AM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
10:01AM	CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
08:00AM	SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award (GlobeNewswire)
Apr-29-25 09:10AM	CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains? (Zacks)
02:02AM	Why CG Oncology, Inc. (CGON) Surged on Monday (Insider Monkey)
Apr-28-25 04:05PM	CG Oncology Soars On Its Johnson & Johnson-Rivaling Cancer Drug (Investor's Business Daily) +25.03%
11:14AM	CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why (Benzinga)
10:24AM	CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug (Investor's Business Daily)
Apr-26-25 04:10PM	CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting (GlobeNewswire)
Apr-24-25 08:00AM	CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025 (GlobeNewswire)
Apr-11-25 05:30AM	How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs (The Wall Street Journal) +9.36%
Apr-02-25 12:32PM	CG Oncology Looks Attractive At Current Prices (Rating Upgrade) (Seeking Alpha)
Mar-31-25 09:55AM	Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade (Zacks) -7.31%
08:00AM	CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates (GlobeNewswire)
05:54AM	Company News for Mar 31, 2025 (Zacks)
Mar-28-25 07:00AM	CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates (GlobeNewswire)
Mar-26-25 05:45PM	Is CG Oncology (CGON) Among the Best IPO Stocks to Buy in 2025? (Insider Monkey)
Mar-24-25 08:00AM	Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy (GlobeNewswire) +5.47%
Mar-12-25 08:00AM	CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates (GlobeNewswire)
Feb-26-25 08:00AM	CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-25-25 09:49AM	Is CG Oncology, Inc. (CGON) An Oversold Biotech Stock to Buy Now? (Insider Monkey) -6.65%
Feb-23-25 01:29PM	Why CG Oncology, Inc. (CGON) is the Most Oversold Pharma Stock to Buy According to Analysts (Insider Monkey)
Feb-20-25 12:19PM	Why CG Oncology (CGON) Is the Most Oversold Healthcare Stock to Buy Now (Insider Monkey)
Jan-16-25 09:55AM	Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect? (Zacks)
Jan-03-25 10:00AM	How to Navigate the Stock and Bond Markets in 2025 (The Wall Street Journal) +5.35%
Dec-16-24 04:05PM	CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-12-24 08:19PM	CG Oncology Announces Pricing of Public Offering (GlobeNewswire) -9.01%
Dec-11-24 06:17AM	CG Oncology Announces Proposed Public Offering (GlobeNewswire) -5.85%
Dec-06-24 08:00AM	SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award (GlobeNewswire)
07:10AM	CG Oncology announces data from Phase 3 BOND-003 trial (TipRanks)
Dec-05-24 11:35AM	CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate (Benzinga) -6.54%
07:00AM	Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Dec-02-24 08:00AM	CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024 (GlobeNewswire)
Nov-20-24 08:00AM	CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting (GlobeNewswire)
Nov-12-24 08:00AM	CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.83%
Nov-11-24 08:00AM	CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer (GlobeNewswire)
Sep-14-24 05:25PM	Cg Oncology Inc. (CGON): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Aug-30-24 08:00AM	CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-08-24 08:23AM	CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +7.02%
Jun-18-24 08:00AM	CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec (GlobeNewswire)
Jun-06-24 12:14PM	CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC (GlobeNewswire)
May-24-24 08:00AM	CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting (GlobeNewswire) +9.07%
May-11-24 10:16AM	ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 01:54PM	CGON Stock Earnings: CG Oncology Misses EPS for Q1 2024 (InvestorPlace) -7.43%
08:00AM	CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-03-24 11:23AM	Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (GlobeNewswire) -8.18%
Apr-26-24 08:00AM	CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024 (GlobeNewswire) +13.26%
Apr-24-24 10:00AM	CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024 (GlobeNewswire)
Apr-11-24 10:02PM	20 Countries with the Most Domestically Listed Companies in the World (Insider Monkey)
Mar-28-24 08:00AM	CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting (GlobeNewswire) +7.07%
Feb-27-24 08:00AM	CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Jan-30-24 07:00AM	CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire)
Jan-26-24 04:20PM	In Bad News for IPO Market, BrightSpring Closes Below Offering Price (The Wall Street Journal) -5.76% +5.62%
Jan-24-24 07:10PM	CG Oncology Announces Pricing of Upsized Initial Public Offering (Business Wire)

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mulay James	Director	Jan 09 '26	Option Exercise	12.07	11,145	134,515	10,491	Jan 13 04:15 PM
Mulay James	Director	Jan 09 '26	Sale	52.47	11,145	584,799	0	Jan 13 04:15 PM
JAMES MULAY	Director	Jan 09 '26	Proposed Sale	41.93	13,109	549,660		Jan 09 04:32 PM
POST LEONARD E	Director	Nov 17 '25	Option Exercise	0.60	1,000	600	1,000	Nov 18 04:30 PM
POST LEONARD E	Director	Nov 17 '25	Sale	41.43	1,000	41,430	0	Nov 18 04:30 PM
POST LEONARD E	Director	Oct 13 '25	Option Exercise	0.60	1,000	600	1,000	Oct 15 04:15 PM
POST LEONARD E	Director	Oct 13 '25	Sale	43.25	1,000	43,250	0	Oct 15 04:15 PM
Mulay James	Director	Oct 09 '25	Option Exercise	3.72	5,903	21,959	5,903	Oct 10 04:15 PM
Mulay James	Director	Oct 09 '25	Sale	43.99	5,903	259,673	0	Oct 10 04:15 PM
JAMES MULAY	Director	Oct 09 '25	Proposed Sale	40.71	6,557	266,935		Oct 09 04:19 PM
POST LEONARD E	Director	Sep 30 '25	Option Exercise	0.60	5,000	3,000	5,000	Oct 01 05:07 PM
POST LEONARD E	Director	Sep 30 '25	Sale	40.09	5,000	200,450	0	Oct 01 05:07 PM
Mulay James	Director	Sep 29 '25	Option Exercise	1.82	12,755	23,214	12,755	Sep 30 04:38 PM
Mulay James	Director	Sep 29 '25	Sale	39.19	12,755	499,868	0	Sep 30 04:38 PM
LEONARD E POST	Director	Sep 30 '25	Proposed Sale	39.08	5,000	195,400		Sep 30 04:27 PM
Mulay James	Director	Sep 18 '25	Option Exercise	1.82	19,112	34,784	19,112	Sep 22 07:30 AM
Mulay James	Director	Sep 19 '25	Option Exercise	1.82	3,574	6,505	3,574	Sep 22 07:30 AM
Mulay James	Director	Sep 18 '25	Sale	39.01	19,112	745,559	0	Sep 22 07:30 AM
Mulay James	Director	Sep 19 '25	Sale	38.99	3,574	139,350	0	Sep 22 07:30 AM
JAMES MULAY	Director	Sep 18 '25	Proposed Sale	37.72	35,441	1,336,835		Sep 18 04:28 PM
POST LEONARD E	Director	Sep 15 '25	Option Exercise	0.60	1,000	600	1,000	Sep 16 04:15 PM
POST LEONARD E	Director	Sep 15 '25	Sale	35.10	1,000	35,100	0	Sep 16 04:15 PM
LEONARD E POST	Director	Sep 15 '25	Proposed Sale	33.34	3,000	100,020		Sep 15 04:30 PM
Liu Brian Guan-Chyun	Director	Sep 11 '25	Buy	33.00	1,515,151	49,999,983	1,515,151	Sep 15 08:32 AM
Mulay James	Director	Sep 05 '25	Option Exercise	0.60	27,015	16,209	27,015	Sep 08 04:16 PM
Mulay James	Director	Sep 05 '25	Sale	31.53	27,015	851,797	0	Sep 08 04:16 PM
JAMES MULAY	Director	Sep 05 '25	Proposed Sale	30.94	27,015	835,844		Sep 05 04:24 PM
Song Hong Fang	Director	Sep 03 '25	Sale	27.80	100,000	2,779,542	2,903,931	Sep 04 05:00 PM
POST LEONARD E	Director	Sep 03 '25	Option Exercise	0.60	1,000	600	1,000	Sep 04 04:30 PM
POST LEONARD E	Director	Sep 03 '25	Sale	28.00	1,000	28,000	0	Sep 04 04:30 PM
Charming Jade Ltd	Director	Sep 03 '25	Proposed Sale	27.46	100,000	2,746,000		Sep 03 05:06 PM
LEONARD E POST	Director	Sep 03 '25	Proposed Sale	27.46	1,000	27,460		Sep 03 04:29 PM
POST LEONARD E	Director	Jul 17 '25	Option Exercise	0.60	2,000	1,200	2,000	Jul 18 04:30 PM
POST LEONARD E	Director	Jul 17 '25	Sale	28.00	2,000	56,000	0	Jul 18 04:30 PM
LEONARD E POST	Director	Jul 17 '25	Proposed Sale	26.08	2,000	52,160		Jul 17 04:22 PM
POST LEONARD E	Director	May 21 '25	Option Exercise	0.60	1,000	600	1,000	May 22 04:15 PM
POST LEONARD E	Director	May 21 '25	Sale	28.00	1,000	28,000	0	May 22 04:15 PM
POST LEONARD E	Director	Apr 28 '25	Option Exercise	0.60	1,000	600	1,000	Apr 29 04:15 PM
POST LEONARD E	Director	Apr 28 '25	Sale	30.76	1,000	30,760	0	Apr 29 04:15 PM
POST LEONARD E	Director	Mar 17 '25	Option Exercise	0.60	1,000	600	1,000	Mar 18 04:30 PM
POST LEONARD E	Director	Mar 17 '25	Sale	28.00	1,000	28,000	0	Mar 18 04:30 PM
LEONARD E POST	Director	Mar 17 '25	Proposed Sale	27.80	4,000	111,200		Mar 17 04:38 PM
POST LEONARD E	Director	Feb 18 '25	Option Exercise	0.60	1,000	600	1,000	Feb 19 04:15 PM
POST LEONARD E	Director	Feb 18 '25	Sale	28.61	1,000	28,610	0	Feb 19 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CGON

Cg Oncology Inc

Upgrade your FINVIZ experience